Apixaban Prophylaxis for Prevention of Left Ventricular Thrombus Following Anterior Myocardial In… (NCT06742567) | Clinical Trial Compass
RecruitingPhase 3
Apixaban Prophylaxis for Prevention of Left Ventricular Thrombus Following Anterior Myocardial Infarction
Pakistan472 participantsStarted 2024-12-02
Plain-language summary
The objective of this randomized controlled trial is to compare the safety and efficacy of low dose Apixaban (2.5 mg bid) in addition to guideline directed medical therapy vs guideline directed medical therapy alone in the prevention of left ventricular thrombus formation (after 30-days) following primary PCI in patients with acute anterior myocardial infarction with severe LV dysfunction.
Who can participate
Age range
18 Years – 75 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients aged 18-65 years
* Presenting with acute anterior STEMI
* Severe LV dysfunction (EF\<35%) with antero-apical akinesis, dyskinesis, or aneurysm
* WIHTOUT evidence of LV thrombus.
Exclusion Criteria:
* Patients with previous anterior myocardial infarction or LAD revascularization procedures
* Patients with cardiogenic shock
* Patients with LV thrombus
* Patients with advanced CKD (Cr \> 2 and those on hemodialysis)
* Recent ICH or major bleed requiring transfusion, low platelet counts \<100,000
* History of recent CVA ( within past three months)
* Patients with atrial fibrillation or other indications for chronic anticoagulation
* Pregnant patients and those with hematological disorders
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Incidence of LV thrombus formation in the treatment arm vs. control group
Timeframe: one month
Trial details
NCT IDNCT06742567
SponsorNational Institute of Cardiovascular Diseases, Pakistan